Chapter 8

Scenarios and Watch

The report's parts now sit on the table: a subscription franchise with retention above 95%, a de-rating from $495.72 to $262.46, organic growth re-accelerating to 7.1%, a margin trough, and an AI question that cuts both ways. This chapter reconciles them. At $262.46 the market pays roughly 15x forward adjusted earnings for a business growing organic subscriptions in the mid-single digits — a price that sits just above the sell-side mean target of $254 and implies almost no long-run growth, while the operating momentum that would justify more is real but not yet proven durable.

Where the reference points stand

Sources: share price and consensus targets/estimates per market data feed, as of 16–17 Jul 2026; FY2026 adjusted EPS guidance $17.25–$17.75 midpoint, Q3 FY2026 earnings presentation [1].

The current price is the tension in one line. It has recovered from a 52-week low of $190.06 but remains roughly 47% below the November 2024 peak, and it now trades a few dollars above the sell-side mean target of $254 and above the median of $246.50 — so the average analyst sees the stock as slightly ahead of fair value even after the de-rating. The margin-of-safety case (Margin of Safety) rests not on that target but on the reverse-DCF: at $262.46 the price discounts only about 2.3% perpetual free-cash-flow growth, against organic subscription growth that has just printed 7.1%. The report's central question is whether that gap is opportunity or a fair price for a franchise that has stopped compounding at its historic rate.

The state of play, reconciled

Each row below is a fact the report has established, read two ways, with the evidence that would settle it. None of these is decided by rhetoric; each is decided by a specific disclosure on a specific date.

Established fact	The constructive read	The skeptical read	What settles it
Organic ASV growth reached 7.1% in Q3 FY2026 — the fifth straight quarter of acceleration and the fastest since Q1 FY2024	A genuine inflection: sales execution and AI demand are re-igniting the top line	Still below the high-single/double-digit rates of the franchise's best years, and Q3 is aided by a seasonally strong close; the industry itself grows ~6.5%	FY2027 organic ASV guidance and the Q4 (seasonally largest) print, both due 17 Sep 2026
Over 10% of Q3 ASV growth came directly from AI SKUs; over 20% of the top 100 clients use MCP on a paid basis	The AI flywheel is monetizing — connected data and embedded workflows are proving to be a moat, not a vulnerability	Discrete AI revenue is still small against a $2.5B base, and a large index/ratings peer frames generative AI as a disintermediation threat to the data-terminal model	Disclosure of discrete AI-SKU ASV and whether AI consumption sustains retention and product upsizing
Adjusted operating margin is guided to 34.0%–35.5% for FY2026, down from the 36%–37% guided a year earlier	An investment trough — the new team sees a "clear path to expanding margins" once the technology-consolidation spend rolls off	The step-down could prove structural if AI infrastructure, token, and compensation costs stay elevated	The FY2027 margin guide on 17 Sep 2026 — recovery toward 36% versus another flat year
At $262.46 the price implies ~2.3% perpetual FCF growth and trades near 15x forward adjusted EPS	Undemanding for an above-95%-retention franchise re-accelerating to 7.1% — the priced-in pessimism is the opportunity	Not absolutely cheap for a mid-single-digit grower, and the price already sits above the sell-side mean target	Whether estimate revisions — currently trending up — keep rising and pull targets above spot

The four rows share one hinge: the fiscal 2027 outlook management issues alongside Q4 results on 17 September 2026. It is the first hard read on whether the ASV acceleration and the AI monetization survive into a fresh guidance year, and whether the margin step-down was a trough or a new level.

The improving trajectory management has already signaled

Through fiscal 2026 the company raised its own guidance once and then held it — organic ASV guidance moved up at the second quarter and the adjusted-EPS range with it, then both were reaffirmed at the third quarter. That is the shape of a business meeting a plan rather than chasing one.

Source: FY2026 adjusted EPS guidance revised from $16.90–$17.60 (18 Dec 2025) to $17.25–$17.75 (31 Mar 2026) and reaffirmed (1 Jul 2026), FactSet earnings presentations [2] [3].

The current fiscal-2026 outlook — organic ASV growth of $130M–$160M (~5.4% to ~6.7%), revenue of $2,450M–$2,470M, and adjusted EPS of $17.25–$17.75 [4] — brackets the base case below. What the guidance does not yet answer is fiscal 2027, and that is where the three scenarios diverge.

Three ways the next two years resolve

The scenarios below hold the through-line's variables — ASV durability, AI monetization, and the margin trough — at three settings, and attach the fair-value bounds the valuation work derived (Margin of Safety). They are not probabilities; they are the range the evidence currently supports and the drivers that move a reader between them.

Sources: driver settings anchored to FY2026 guidance [5] and Q3 FY2026 AI-monetization disclosure [6]; fair-value bounds derived in the valuation analysis (Margin of Safety).

The base case is close to what the company already guides and what consensus already carries: revenue near $2.47B in FY2026 and adjusted EPS building toward the FY2027 consensus of $19.67, roughly 10.5% above FY2026. At $262.46 the price is inside the lower half of the base-case fair-value band, which is why the sell-side mean sits a touch below spot rather than far above it — the moderate-growth outcome is largely in the price. The asymmetry a value buyer is paid for lives in the bull column: if the 7.1% ASV rate and the AI flywheel prove durable and the margin trough reverses, the combination of faster growth and a re-rated multiple reaches the high-$300s. The bear column is the discipline on that hope — a re-deceleration toward the industry's ~6.5% ceiling with a margin that does not recover pulls fair value back toward, and below, today's price.

What to watch, and what would move the read

Watch items are only useful if they are falsifiable. Each row names the event, the line item, the threshold that changes the read, and which way the surprise risk runs. They are ordered by decision value.

Sources: next earnings date and revision data per market data feed (as of 17 Jul 2026); FY2026 guidance [7]; AI-SKU and MCP metrics from the Q3 FY2026 call [8] [9]; CEO priorities [10].

Two details sharpen the top watch item. First, the September print is the highest-information event on the calendar precisely because recent quarters have been quiet: the last three reports beat consensus by only 3.5%, 1.9%, and 1.8%, so a fiscal-2027 guide is where a real surprise can come from, not the quarter's EPS. Second, the one recent miss was the fiscal-2025 fourth quarter reported in September 2025 — the same seasonally largest quarter — which is why a strong FY2027 guide would carry more weight than usual, and a soft one more sting.

The execution machinery behind the numbers is new and still unproven. CEO Sanoke Viswanathan, a 15-year JPMorgan veteran who ran its international consumer and wealth business, joined in September 2025 [11] and set three priorities: commercial excellence, productivity, and long-term strategy [12]. The commercial-excellence program — re-cut sales incentives, disciplined pipeline, tighter pricing — is the mechanism that would keep ASV growth at 7% rather than let it fade to the industry rate; the productivity program, consolidating legacy technology onto a modern platform, is the mechanism that would reverse the margin trough. Both are asserted, not yet demonstrated. The scoreboard is the same two numbers already in the watch list: organic ASV growth and adjusted operating margin. Roughly ten months in, the ASV line is cooperating and the margin line is not — which is exactly the split the September guide has to resolve.

What remains genuinely undecided

The report can state plainly what it knows: the balance sheet makes bankruptcy risk remote (De-Rated Compounder), retention above 95% every year makes the subscription base durable (Moat and AI), and the de-rating has removed the premium the stock once carried (Margin of Safety). What it cannot yet state is whether the 7.1% ASV acceleration is a durable inflection or a cyclical bounce flattered by a seasonally strong close, and whether the margin step-down reverses. At $262.46 — just above the sell-side mean and pricing in barely 2% long-run growth — a buyer is paid a modest margin of safety to wait for that answer, with the downside bounded by a franchise that does not break and the upside gated by a re-acceleration that is real but unproven at the margin. The fiscal-2027 guidance on 17 September 2026 is the first date that converts the question into evidence.